DATA AVAILABILITY STATEMENT : The data presented in this study are available on request from the corresponding author. The data are not publicly available due to limited space for the manucrsipt.
CONFLICTS OF INTEREST : Frederik L. Giesel has a patent application for quinolone-based FAP-targeting agents for imaging and therapy. He also has shares of a consultancy group for iTheranostics and is also a medical advisor for ABX Advanced Biochemical Compound, Sofie Biosciences, Telix Pharmaceuticals, and Alpha Fusion. The other authors have no relevant financial or non-financial interests to disclose.